Workflow
GeneDx (WGS)
icon
Search documents
GeneDx Surges Past Q2 Expectations, Sets Up For Strong Year-End Growth
Seeking Alpha· 2025-07-31 14:22
Analyst’s Disclosure:I/we have a beneficial long position in the shares of WGS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. SOME STOCKS MENTIONED CAN ALREADY BE PART OF THE PORTFOLIOS OF FAMILY AND ASSOCIATES and retirement accounts, and can be bought/sold in the next ...
GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-07-29 23:25
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In Lockheed Martin (LMT) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in GeneDx and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims ag ...
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
ZACKS· 2025-07-29 14:51
Core Insights - GeneDx Holdings Corp. reported a significant turnaround in Q2 2025 with adjusted diluted EPS of 50 cents, compared to a loss of 8 cents per share in the same period last year, exceeding estimates by 400% [1][8] - Total revenues for the quarter increased by 45.6% year over year to $102.7 million, surpassing the Zacks Consensus Estimate by 21.2% [2][9] - The company achieved a gross profit of $70.9 million, reflecting a 65.1% year-over-year increase, with gross margin expanding by 813 basis points to 69% [3][9] Revenue Performance - Exome and genome test revenues grew by 69% year over year, reaching $85.9 million [2][9] - The company crossed the $100 million revenue mark for the first time, marking a significant milestone [9] Expense and Profitability Metrics - Adjusted total operating expenses were $61.9 million, an increase of 15.7% year over year, leading to an operating profit of $9 million compared to an operating loss of $10.6 million in the previous year [4][9] - Selling and marketing expenses rose by 17.3% to $19.4 million, while general and administrative expenses increased by 5.3% to $27.4 million [3] Cash Position - At the end of Q2 2025, GeneDx had cash, cash equivalents, and marketable securities totaling $134.6 million, down from $159.2 million at the end of Q1 2025 [5] Future Outlook - The company raised its full-year 2025 sales guidance to a range of $400-$415 million from the previous $360-$375 million, with the Zacks Consensus Estimate currently at $371.3 million [6] - Adjusted net income for the year is expected to be positive, with earnings estimated at $1.13 per share [6] Strategic Developments - During the quarter, GeneDx advanced its growth strategy by acquiring Fabric Genomics, which supports a hybrid model for delivering genomic insights globally [10] - The company also expanded its commercial focus to include inborn errors of immunity as a new indication for its genetic testing [10]
GeneDx (WGS) - 2025 Q2 - Earnings Call Transcript
2025-07-29 13:32
GeneDx (WGS) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Company ParticipantsSabrina Dunbar - Director - IR & CommunicationsKatherine Stueland - CEO, President & DirectorKevin Feeley - CFOSubbu Nambi - Managing DirectorBrandon Couillard - Managing DirectorTycho Peterson - MD - Global EquitiesConference Call ParticipantsDavid Westenberg - MD & Senior Research AnalystDaniel Brennan - MD & Senior Equity Research AnalystWilliam Bonello - Senior Research AnalystMark Massaro - MD & Senior Equity Research Anal ...
GeneDx (WGS) - 2025 Q2 - Earnings Call Transcript
2025-07-29 13:30
GeneDx (WGS) Q2 2025 Earnings Call July 29, 2025 08:30 AM ET Speaker0Day and thank you for standing by. Welcome to the GeneDx Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone.You will then hear an automated message advising your hand is raised. To withdraw your question, please press ...
GeneDx Holdings Corp. (WGS) Q2 Earnings and Revenues Beat Estimates
ZACKS· 2025-07-29 12:41
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to a loss of $0.11 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +400.00%. A quarter ago, it was expected that this company would post earnings of $0.11 per share when it actually produced earnings of $0.28, delivering a surprise of +154.55%.Over the last four quarters, the com ...
GeneDx (WGS) - 2025 Q2 - Earnings Call Presentation
2025-07-29 12:30
GeneDx (Nasdaq: WGS) 2Q 2025 Earnings Presentation July 29, 2025 On average: 16 tests and 5 years before an accurate diagnosis Forward Looking Statements This presentation contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance, future operations, plans, objectives of management, and our market opportunity, including our expected full year 2025 reported revenue, volume, adjusted gross margin and adjusted net income. ...
GeneDx (WGS) - 2025 Q2 - Quarterly Report
2025-07-29 12:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Commission file number 001-39482 GeneDx Holdings Corp. 333 Ludlow Street, North Tower; 6th Floor Stamford, Connecticut 06902 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: (888) 729-1206 Securities registered pursuant to Section 12(b) of ...
GeneDx (WGS) - 2025 Q2 - Quarterly Results
2025-07-29 11:21
Exhibit 99.1 GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights GAITHERSBURG, Md., July 29, 2025 — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second quarter of 2025. "Crossing the $100 million revenue mark and delivering our fourth consecutive profitable quarter is a major milestone for GeneDx, putting us on a path for more growth at scale and enabling us to reach more p ...
Why GENEDX HOLDINGS (WGS) Could Beat Earnings Estimates Again
ZACKS· 2025-07-28 17:10
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? GeneDx Holdings Corp. (WGS) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.When looking at the last two reports, this company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 202.27%, on average, in the last two quarters.For the last reported quarter, GENE ...